Drug intelligence / Profile preview

VM-PSY-004

Development stage: Unknown
Lead developer: VivaMed
Modality: Small Molecules
Administration: Oral

Overview

VM-PSY-004 is a small molecule drug candidate being developed by VivaMed BioPharma for the treatment of Tobacco Use Disorder (smoking cessation). Currently in Phase 2 clinical development, VM-PSY-004 is a proprietary formulation of cytisine, a plant-derived alkaloid. It functions as a selective partial agonist of the alpha-4 beta-2 (α4β2) nicotinic acetylcholine receptors in the brain. By binding to these receptors, VM-PSY-004 helps to mitigate the symptoms of nicotine withdrawal and reduces the reinforcing effects of nicotine by partially blocking its ability to stimulate the mesolimbic dopamine system. This mechanism is similar to that of varenicline, providing a therapeutic pathway to assist individuals in quitting tobacco use.

Other names: cytisine

Targets

CHRNA4 (nAChR α4)CHRNB2 (nAChR β2 subunit)

Beyond the preview

Go deeper on VM-PSY-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VM-PSY-004.

Explore the full profile